In:
International Journal of Cancer, Wiley, Vol. 142, No. 1 ( 2018-01), p. 156-164
Abstract:
What's new? Advancing precision medicine has become a priority in many countries. The current protocol for personalized cancer therapy involves genotyping tumors in search of various driver mutations and selecting individual tyrosine kinase inhibitors accordingly. But although promising, the genotype approach has several limitations. Here, the authors show for the first time that a phosphoarray platform examining the activity of multiple kinases simultaneously is also capable of individualizing kinase inhibitor therapy in head and neck squamous cell carcinoma. The results provide the proof of concept that the phosphoarray technology can be further developed into a new diagnostic platform for personalized cancer therapy.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8